The upside of being a digital pharma player
Journal
Drug Discovery Today
ISSN
1359-6446
Type
journal article
Date Issued
2020
Author(s)
Abstract (De)
We investigated the state of artificial intelligence (AI) in pharmaceutical research and development
(R&D) and outline here a risk and reward perspective regarding digital R&D. Given the novelty of the
research area, a combined qualitative and quantitative research method was chosen, including the
analysis of annual company reports, investor relations information, patent applications, and scientific
publications of 21 pharmaceutical companies for the years 2014 to 2019. As a result, we can confirm that
the industry is in an ‘early mature’ phase of using AI in R&D. Furthermore, we can demonstrate that,
despite the efforts that need to be managed, recent developments in the industry indicate that it is
worthwhile to invest to become a ‘digital pharma player’.
(R&D) and outline here a risk and reward perspective regarding digital R&D. Given the novelty of the
research area, a combined qualitative and quantitative research method was chosen, including the
analysis of annual company reports, investor relations information, patent applications, and scientific
publications of 21 pharmaceutical companies for the years 2014 to 2019. As a result, we can confirm that
the industry is in an ‘early mature’ phase of using AI in R&D. Furthermore, we can demonstrate that,
despite the efforts that need to be managed, recent developments in the industry indicate that it is
worthwhile to invest to become a ‘digital pharma player’.
Language
English
HSG Classification
contribution to scientific community
HSG Profile Area
None
Refereed
Yes
Publisher
Elsevier Science
Pages
6
Subject(s)
Division(s)
Eprints ID
260763